Ki-67 gene expression
Ki-67 serves as a prominent cancer marker. We describe how expression of the MKI67 gene coding for Ki-67 is controlled during the cell cycle. MKI67 mRNA and Ki-67 protein are maximally expressed in G 2 phase and mitosis. Expression is dependent on two CHR elements and one CDE site in the MKI67 promo...
Gespeichert in:
Veröffentlicht in: | Cell death and differentiation 2021-12, Vol.28 (12), p.3357-3370 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Ki-67 serves as a prominent cancer marker. We describe how expression of the
MKI67
gene coding for Ki-67 is controlled during the cell cycle.
MKI67
mRNA and Ki-67 protein are maximally expressed in G
2
phase and mitosis. Expression is dependent on two CHR elements and one CDE site in the
MKI67
promoter. DREAM transcriptional repressor complexes bind to both CHR sites and downregulate the expression in G
0
/G
1
cells. Upregulation of
MKI67
transcription coincides with binding of B-MYB-MuvB and FOXM1-MuvB complexes from S phase into G
2
/M. Importantly, binding of B-MYB to the two CHR elements correlates with loss of CHR-dependent
MKI67
promoter activation in B-MYB-knockdown experiments. In knockout cell models, we find that DREAM/MuvB-dependent transcriptional control cooperates with the RB Retinoblastoma tumor suppressor. Furthermore, the p53 tumor suppressor indirectly downregulates transcription of the
MKI67
gene. This repression by p53 requires p21/CDKN1A. These results are consistent with a model in which DREAM, B-MYB-MuvB, and FOXM1-MuvB together with RB cooperate in cell cycle-dependent transcription and in transcriptional repression following p53 activation. In conclusion, we present mechanisms how
MKI67
gene expression followed by Ki-67 protein synthesis is controlled during the cell cycle and upon induction of DNA damage, as well as upon p53 activation. |
---|---|
ISSN: | 1350-9047 1476-5403 |
DOI: | 10.1038/s41418-021-00823-x |